Multitarget Strategy for Primary Podocytopathies

Recruiting now · Not applicable

Conditions studied: Nephrotic Syndrome

In brief

The goal of this clinical trial is to verify whether a cell culture system can be used to evaluate the presence of a factor capable of causing proteinuria in the serum of patients with primary podocytopathies. This system will also be used to evaluate the in vitro efficacy of a combined therapy for the treatment of this disorder. Researchers will compare samples from patients with primary podocytopathies with those obtained from healthy subjects and patients with other renal disorders. Participants will be asked to visit the clinic at regular intervals for up to 36 months, and to provide blood and urine samples (and a sample of the discarded plasmapheresis effluent in case the procedure is performed).

Key facts

Study ID: NCT06718894
Run by: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
People needed: 150
Starts: 2025-06-19
Expected to finish: 2032-11-01
Last updated by the study team: 2026-03-27

Who can join

Age: any. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Signature of informed consent for study participation
One of the following conditions:
Patients with primary podocytopathies (with a histological diagnosis of FSGS or MCD) showing clinical and/or histological evidence of post-transplant recurrence.
Patients with primary podocytopathies (with a histological diagnosis of FSGS or MCD) without clinical and/or histological evidence of post-transplant recurrence.
Patients with primary podocytopathies in their native kidneys in an active clinical phase of the disease.
Patients with podocytopathies presenting clinical features compatible with a secondary form due to another condition.
Patients with glomerulonephritis other than primary podocytopathies (e.g., IgA nephropathy, systemic lupus erythematosus, membranous nephropathy).
Patients with no history of renal diseases

You may not qualify if…

Subjects affected by primary podocytopathies or other glomerulonephritides in clinical remission or with ESRD (eGFR < 15 ml/min) and/or on renal replacement therapy
Individuals unable to understand and consent to the study procedures
Any clinical condition that, according to the investigator's judgment, could compromise patient safety during study participation

Where it is running

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico — Milan, Italy (enrolling)
Fondazione IRCCS Policlinico San Matteo — Pavia, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.